For professional members, Industry Connect presents free-market perspectives on pressing issues affecting key industries today, featuring dynamic conversations with top business leaders and policy experts from health care to finance, and technology to energy.
Pfizer is spearheading one of the most promising vaccines for the current scourge, developed at record speed. What important role did free enterprise play in this development? What accounts for the vaccine’s quick development? What regulatory lessons are there for future drug and vaccine development? Join us at this members-only professional event for an insider look at the drug and vaccine development landscape. This event will be an important complement to the December 9 Adam Smith Society conversation with Richard Epstein on the role of the FDA.
Robert Popovian is currently Vice President, US Government Relations at Pfizer Inc. Robert brings over two decades of experience in numerous facets of biopharmaceutical and health care industry with a strong track record of expertise in Health Care Policy and Economics, Government Relations, Medical Affairs, and Strategic Planning.
Robert has published and presented extensively on the impact of biopharmaceuticals and health policies on health care costs and clinical outcomes, including authorship in clinical and healthcare delivery journals and published expert source in The Hill, Los Angeles Times, USA Today, Pink Sheet and Managed Healthcare Executive amongst many others. He also writes a regularly published column in Morning Consult. He is a sought-out speaker at healthcare policy and medical conferences on topics such as payment and delivery reform, pricing, reimbursement, biosimilars, biopharmaceutical innovation and health economics. He currently serves on the Board of Councilors of University of Southern California, School of Pharmacy and Board of Advisors for Capital RX.
He is one of the few researchers who has studied and published both clinical and policy related economic analysis as well as one of a handful who have studied and published empirical data regarding emerging payment models in the US healthcare system and for biopharmaceutical reimbursement. He was also one of the first to secure inclusion of health outcomes data regarding labeled indication of a biopharmaceutical.
Robert completed his Doctorate in Pharmacy and Master of Science in Pharmaceutical Economics and Policy degrees at the University of Southern California with honors. He has also completed a residency in Pharmacy Practice/Adult Internal Medicine and Infectious Diseases at the Los Angeles County – University of Southern California Hospital and a fellowship in Pharmaceutical Economics and Policy at University of Southern California.
Robert is married to Maylin Megran Popovian; they have two daughters, Katrina and Natalya. They have residences both in Los Angeles, CA and Washington, DC.